Keyword: Pharmaceutical Care Management Association
Democrats have officially revealed a plan to let people ages 50 and over buy in to Medicare, plus more insurance news.
PBMs are hitting back against critics who blame them for rising drug prices, as the system they use to negotiate rebates hangs in the balance.
The Trump administration wants to eliminate safe harbor protections for drug rebates negotiated by pharmacy benefit managers.
UnitedHealthcare will pull out of the Health Care Cost Institute research collaborative, plus more insurance headlines.
A report backed by New York pharmacists found that PBMs are marking up generics in the state's Medicaid program. The group is calling for an audit.
Despite railing against the role of middlemen—namely PBMs—in rising drug prices, HHS appears poised to introduce some into Part B.
CMS wants drug companies to put their list prices in television ads, but whether that policy is something it can enforce remains a major question.
The policy change will generate cost savings that MA plans can pass on to consumers, the agency says.
The Trump administration is considering a proposal to overhaul safe harbor protections for pharmaceutical company rebates.
As the Trump administration takes aim at rising drug costs, healthcare organizations are weighing in on proposals from its plan to address the issue.